Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB.

J Natl Cancer Inst. 1996 Jan 17;88(2):123-5. No abstract available.

PMID:
8537973
2.

Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen.

Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB, Sporn MB.

Cancer Res. 1994 Sep 1;54(17):4614-7.

3.

1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat.

Anzano MA, Smith JM, Uskoković MR, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL, et al.

Cancer Res. 1994 Apr 1;54(7):1653-6.

4.

Localization of transforming growth factor-beta isotypes in lesions of the human breast.

McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, Sporn MB.

Hum Pathol. 1992 Jan;23(1):13-20.

PMID:
1544664
5.

Antibodies to transforming growth factor-beta 2 peptides: specific detection of TGF-beta 2 in immunoassays.

Flanders KC, Cissel DS, Mullen LT, Danielpour D, Sporn MB, Roberts AB.

Growth Factors. 1990;3(1):45-52.

PMID:
2383401
6.

N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat.

Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, Smith JM, Phillips SL, Henderson WR, Mullen LT, Brown CC, Sporn MB.

Cancer Res. 1979 Apr;39(4):1339-46.

Supplemental Content

Loading ...
Support Center